Estrella Immunopharma Overview
Latest ROE for Estrella Immunopharma: 134.74% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow134.74%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for ESLA is 134.74%. That is above the sector sector average of -5.72%. Investors often review this figure alongside Estrella Immunopharma's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, ESLA currently prints 134.74% for ROE, while the sector average sits near -5.72%. That is roughly 2454.6% above the sector mean. Large gaps often invite a closer look at Estrella Immunopharma's growth, margins, and balance sheet.
Return on Equity shows how effectively Estrella Immunopharma converts resources into returns. At 134.74%, ESLA may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting ESLA's ROE (134.74%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
